文献速递淋巴瘤

利妥昔单抗、奥沙利铂、阿糖胞苷、地塞米松(ROAD)化学免疫治疗复发CD20阳性B细胞非霍奇金淋巴瘤患者的长期随访:Mayo Clinic癌症中心研究联盟(MCCRC)MC0485研究结果,该联盟现称为学术与社区癌症研究联合组织(ACCRU)

Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
PubMed 文献 · Am J Hematol · 2017-08-17

该II期 trial 在45例既往接受过一线方案后复发的侵袭性非霍奇金淋巴瘤患者中评估ROAD方案,总缓解率71%,完全缓解率27%,部分缓解率44%,中位总生存26个月,中位无进展生存11个月,3/4级神经毒性发生率4%,无3/4级肾毒性。作者认为ROAD是复发侵袭性非霍奇金淋巴瘤可接受的挽救治疗选择。

要点

  • ROAD方案每21天给药,总缓解率71%,完全缓解率27%,部分缓解率44%。
  • 中位总生存26个月(95%CI:7.3个月-未达到),中位无进展生存11个月(95%CI:6-104个月)。
  • 3/4级神经毒性发生率4%,无3/4级肾毒性;44%患者以门诊方式接受ROAD。

核心结论

  • ROAD方案是复发侵袭性非霍奇金淋巴瘤患者可接受的挽救治疗选择。

研究设计与样本

  • II期临床试验,2006年至2008年间入组45例符合条件的患者。
  • 患者中位年龄69岁;96%既往接受过利妥昔单抗;53%距诊断在1年内。
  • ROAD每21天给药:利妥昔单抗375 mg/m2静脉 weekly×4次(仅第1周期);地塞米松40 mg口服/静脉第2-5天;奥沙利铂130 mg/m2静脉第2天;阿糖胞苷2000 mg/m2静脉第2-3天共两次;聚乙二醇非格司亭6 mg皮下第4天。
  • 中位接受周期数为2(范围1-6);44%患者以门诊方式接受ROAD。

主要发现

  • 总缓解率71%,其中完全缓解27%(12/45),部分缓解44%(20/45)。
  • 全部患者中44%(20/45)以及2周期后缓解患者中69%(18/26)接受了移植。
  • 中位总生存26个月(95%CI:7.3个月-未达到),中位无进展生存11个月(95%CI:6-104个月)。
  • 无3/4级肾毒性;3/4级神经毒性发生率为4%。
  • 全部患者中42%以及接受移植患者中69%在5年时仍存活。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 - 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty-five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1-6). Forty-four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty-four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos-not reached) and median progression-free survival was 11 mos (95% CI: 6-104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty-two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Witzig TE, Johnston PB, LaPlant BR, et al. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017. PMID: 28614905. doi:10.1002/ajh.24824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。